文献速递糖尿病

REPLACE-BG:在控制良好的1型糖尿病成人中比较仅用连续血糖监测与联用常规血糖监测的随机试验

REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2017-02-16

在14个中心开展随机非劣效性试验,149例仅用CGM、77例CGM联合BGM,26周内两组目标范围内时间分别为63±13%与65±13%,校正差异0%(单侧95%CI -2%),仅CGM组无严重低血糖事件,结论为仅用CGM不劣于CGM联合BGM。

要点

  • 仅用CGM组与CGM+BGM组26周目标范围内时间分别为63±13%与65±13%,校正差异0%(单侧95%CI -2%)。
  • 仅用CGM组每日血糖检测(含校准)2.8±0.9次,CGM+BGM组5.4±1.4次(P<0.001)。
  • 仅用CGM组无严重低血糖事件,CGM+BGM组发生1例。

核心结论

  • 在控制良好、严重低血糖风险低的1型糖尿病成人中,不使用常规确认性血糖监测的CGM与联合BGM同样安全有效。

研究设计与样本

  • 在T1D Exchange Clinic Network的14个中心开展的随机非劣效性临床试验。
  • 纳入年龄≥18岁(平均44±14岁)、1型糖尿病病程≥1年(平均24±12年)、使用胰岛素泵且HbA1c≤9.0%(≤75 mmol/mL)(平均7.0±0.7% [53±7.7 mmol/mol])的成人,研究前47%为CGM使用者。
  • 参与者按2:1随机分配至仅用CGM组(n=149)或CGM+BGM组(n=77),主要结局为26周试验期间目标范围内时间(70-180 mg/dL),预设非劣效界值为7.5%。

主要发现

  • 26周试验期间,仅用CGM组与CGM+BGM组的CGM使用时间分别为平均6.7±0.5天/周与6.8±0.4天/周。
  • 每日血糖检测次数(包括CGM校准所需的每日2次)在仅用CGM组为平均2.8±0.9次,在CGM+BGM组为平均5.4±1.4次(P<0.001)。
  • 仅用CGM组基线及26周时70-180 mg/dL平均时间均为63±13%;CGM+BGM组分别为65±13%与65±11%;校正差异0%(单侧95%CI -2%)。
  • 仅用CGM组未发生严重低血糖事件,CGM+BGM组发生1例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether the use of continuous glucose monitoring (CGM) without confirmatory blood glucose monitoring (BGM) measurements is as safe and effective as using CGM adjunctive to BGM in adults with well-controlled type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: A randomized noninferiority clinical trial was conducted at 14 sites in the T1D Exchange Clinic Network. Participants were ≥18 years of age (mean 44 ± 14 years), had T1D for ≥1 year (mean duration 24 ± 12 years), used an insulin pump, and had an HbA1c ≤9.0% (≤75 mmol/mL) (mean 7.0 ± 0.7% [53 ± 7.7 mmol/mol]); prestudy, 47% were CGM users. Participants were randomly assigned 2:1 to the CGM-only (n = 149) or CGM+BGM (n = 77) group. The primary outcome was time in range (70-180 mg/dL) over the 26-week trial, with a prespecified noninferiority limit of 7.5%. RESULTS: CGM use averaged 6.7 ± 0.5 and 6.8 ± 0.4 days/week in the CGM-only and CGM+BGM groups, respectively, over the 26-week trial. BGM tests per day (including the two required daily for CGM calibration) averaged 2.8 ± 0.9 and 5.4 ± 1.4 in the two groups, respectively (P < 0.001). Mean time in 70-180 mg/dL was 63 ± 13% at both baseline and 26 weeks in the CGM-only group and 65 ± 13% and 65 ± 11% in the CGM+BGM group (adjusted difference 0%; one-sided 95% CI -2%). No severe hypoglycemic events occurred in the CGM-only group, and one occurred in the CGM+BGM group. CONCLUSIONS: Use of CGM without regular use of confirmatory BGM is as safe and effective as using CGM with BGM in adults with well-controlled T1D at low risk for severe hypoglycemia.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes. Diabetes Care. 2017. PMID: 28209654. doi:10.2337/dc16-2482

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。